Truist Financial Corp Sells 16,398 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Truist Financial Corp trimmed its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,372,424 shares of the company’s stock after selling 16,398 shares during the quarter. Truist Financial Corp owned 0.12% of Teva Pharmaceutical Industries worth $30,248,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Smithfield Trust Co raised its stake in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $50,000. Claro Advisors LLC bought a new position in Teva Pharmaceutical Industries in the 3rd quarter worth about $52,000. Venturi Wealth Management LLC bought a new position in Teva Pharmaceutical Industries in the 3rd quarter worth about $60,000. Finally, Ameliora Wealth Management Ltd. bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth about $66,000. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on TEVA shares. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Barclays decreased their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Finally, UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $16.55 on Wednesday. The stock has a 50-day moving average price of $19.93 and a 200-day moving average price of $18.50. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.61 and a debt-to-equity ratio of 2.97. The stock has a market capitalization of $18.74 billion, a P/E ratio of -11.41, a PEG ratio of 1.39 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.